AstraZeneca PLC ADR (AZNN)

Mexico


	Symbol		Exchange		Currency
	AZN		NASDAQ		USD	Real-time
	AZNl		BATS Europe		GBP	Delayed
	AZNs		BATS Europe		SEK	Delayed
	AZNCF		OTC Markets		USD	Delayed
	3LAZ		London		GBP	Real-time
	AZN		London		GBP	Real-time
	3SAZ		London		GBP	Real-time
	AZNN		Mexico		MXN	Delayed
	AZNN		BIVA		MXN	Delayed
	AZN		Stockholm		SEK	Real-time
	AZN		Xetra		EUR	Delayed
	AZN		Frankfurt		EUR	Delayed
	AZN		TradeGate		EUR	Delayed
	AZNPy		TradeGate		EUR	Delayed
	AZNPy		Frankfurt		EUR	Delayed
	AZNm		Buenos Aires		ARS	Delayed
	A1ZN34		B3		BRL	Delayed
	AZNA		Vienna		EUR	Real-time

Currency in MXN

Disclaimer

1,523.99

-26.01(-1.68%)

Closed04:55:26

Fair Value

Day's Range

1,523.99

1,523.99

52 wk Range

1,040.00

1,751.39

AZNN Income Statement

Featured here, the Income Statement (earnings report) for AstraZeneca PLC ADR, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

24,384

26,617

37,417

44,351

45,811

Total Revenues Growth

+10.38%

+9.16%

+40.58%

+18.53%

+3.29%

Cost Of Revenues

4,848

5,246

12,005

8,619

8,040

Gross Profit

19,536

21,371

25,412

35,732

37,771

Gross Profit Growth

+11.09%

+9.39%

+18.91%

+40.61%

+5.71%

Gross Profit Margin %

80.12%

80.29%

67.92%

80.57%

82.45%

Other Operating Expenses, Total

16,468

17,001

22,515

26,720

27,337

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+3.87%	+3.24%	+32.43%	+18.68%	+2.31%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5,349	5,901	8,049	9,529	10,299
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	11,438	11,586	14,673	17,422	18,025
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-319	-486	-207	-231	-987

Operating Income

3,068

4,370

2,897

9,012

10,434

Operating Income Growth

+77.24%

+42.44%

-33.71%

+211.08%

+15.78%

EBIT Margin %

12.58%

16.42%

7.74%

20.32%

22.78%

Net Interest Expenses

-635

-661

-733

-836

-918

Net Interest Expenses Growth

-3.76%

-4.09%

-10.89%

-14.05%

-9.81%

Interest Expense, Total

-780

-738

-776

-917

-1,219

Interest And Investment Income

145

77

43

81

301

Other Non Operating Expenses, Total

-688

-548

-562

-391

-338

EBT, Excl. Unusual Items

1,745

3,161

1,602

7,785

9,178

Gain (Loss) On Sale Of Assets

1,222

1,055

509

216

292

Other Unusual Items, Total

-1,072

-49

-1,869

-1,212

-1,967

EBT, Incl. Unusual Items

1,548

3,916

-265

2,501

6,899

EBT, Incl. Unusual Items Growth

-22.33%

+152.97%

-106.77%

+1,043.77%

+175.85%

EBT, Incl. Unusual Items Margin

6.35%

14.71%

-0.71%

5.64%

15.06%

Income Tax Expense

321

772

-380

-792

938

Net Income to Company

1,227

3,144

115

3,293

5,961

Minority Interest

108

52

-3

-5

-6

Net Income

1,335

3,196

112

3,288

5,955

Net Income Growth

-38.05%

+139.4%

-96.5%

+2,835.71%

+81.11%

Net Income Margin %

5.47%

12.01%

0.3%

7.41%

13%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

1,335

3,196

112

3,288

5,955

Basic EPS - Continuing Operations

1.03

2.44

0.08

2.12

3.84

Basic EPS - Continuing Operations Growth

-39.67%

+137.39%

-96.76%

+2,589.19%

+81%

Diluted EPS - Continuing Operations

1.03

2.44

0.08

2.11

3.81

Diluted EPS - Continuing Operations Growth

-39.64%

+137.39%

-96.76%

+2,571.43%

+80.57%

Basic Weighted Average Shares Outstanding

1,301

1,312

1,418

1,548

1,549

Diluted Weighted Average Shares Outstanding

1,301

1,313

1,427

1,560

1,562

Dividend Per Share

2.8

2.8

2.87

2.9

2.9

Dividend Per Share Growth

0%

0%

+2.5%

+1.05%

0%

EBITDA

5,575

6,990

6,701

13,944

15,010

EBITDA Growth

+24.94%

+25.38%

-4.13%

+108.09%

+7.64%

EBITDA Margin %